latest update:
[TrialBase DB]

trial summary · NCT07885319

Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

A Phase 1b/2, Open-Label, Multicenter, Single-Arm Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Malignant Pleural Mesothelioma, Advanced, sponsored by Ruijin Hospital. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07885319phase PHASE1/PHASE2enrollment 78start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.

Source record: https://clinicaltrials.gov/study/NCT07885319

Facts

registry idNCT07885319
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionMalignant Pleural Mesothelioma, Advanced
sponsorRuijin Hospital
sponsor classOTHER
enrollment78
start date2026-11-01
primary completion2028-11-30
completion2028-11-30
results postednot reported

Conditions

  • Malignant Pleural Mesothelioma, Advanced

Interventions

  • Ivonescimab Combined With Chemotherapy

Countries

  • China

Intervention types: DRUG

Work with this record